ps1145 and Multiple-Myeloma

ps1145 has been researched along with Multiple-Myeloma* in 5 studies

Reviews

1 review(s) available for ps1145 and Multiple-Myeloma

ArticleYear
Novel therapies for multiple myeloma.
    British journal of haematology, 2003, Volume: 120, Issue:1

    Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Enzyme Inhibitors; Estradiol; Heterocyclic Compounds, 3-Ring; Humans; Multiple Myeloma; NF-kappa B; Oxides; Phthalazines; Protease Inhibitors; Protein-Tyrosine Kinases; Pyridines; Thalidomide

2003

Other Studies

4 other study(ies) available for ps1145 and Multiple-Myeloma

ArticleYear
Bortezomib inhibits human osteoclastogenesis.
    Leukemia, 2007, Volume: 21, Issue:9

    In multiple myeloma, the overexpression of receptor activator of nuclear factor kappa B (NF-kappaB) ligand (RANKL) leads to the induction of NF-kappaB and activator protein-1 (AP-1)-related osteoclast activation and enhanced bone resorption. The purpose of this study was to examine the molecular and functional effects of proteasome inhibition in RANKL-induced osteoclastogenesis. Furthermore, we aimed to compare the outcome of proteasome versus selective NF-kappaB inhibition using bortezomib (PS-341) and I-kappaB kinase inhibitor PS-1145. Primary human osteoclasts were derived from CD14+ precursors in presence of RANKL and macrophage colony-stimulating factor (M-CSF). Both bortezomib and PS-1145 inhibited osteoclast differentiation in a dose- and time-dependent manner and furthermore, the bone resorption activity of osteoclasts. The mechanisms of action involved in early osteoclast differentiation were found to be related to the inhibition of p38 mitogen-activated protein kinase pathways, whereas the later phase of differentiation and activation occurred due to inhibition of p38, AP-1 and NF-kappaB activation. The AP-1 blockade contributed to significant reduction of osteoclastic vascular endothelial growth factor production. In conclusion, our data demonstrate that proteasomal inhibition should be considered as a novel therapeutic option of cancer-induced lytic bone disease.

    Topics: Antineoplastic Agents; Apoptosis; Bone Resorption; Boronic Acids; Bortezomib; Cell Differentiation; Cell Lineage; Female; Heterocyclic Compounds, 3-Ring; Humans; In Vitro Techniques; Male; Multiple Myeloma; NF-kappa B; Osteoclasts; p38 Mitogen-Activated Protein Kinases; Pyrazines; Pyridines; RANK Ligand; Signal Transduction; Stem Cells; Transcription Factor AP-1; Vascular Endothelial Growth Factor A

2007
Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor.
    Haematologica, 2005, Volume: 90, Issue:4

    Multiple myeloma is characterized by an accumulation of malignant plasma cells in the bone marrow. Inside the bone marrow, adhesion of myeloma cells to extracellular matrix proteins such as fibronectin may promote cell survival and induce drug resistance. In this work we examined the effect of hepatocyte growth factor (HGF) on the adhesion of myeloma cells and the signaling pathways involved.. Cell adhesion experiments were performed with the human myeloma cell line INA-6 and primary myeloma cells. The HGF signaling pathway was studied in INA-6 cells with the use of antibodies against VLA-4 integrin, and with inhibitors of various intracellular signaling molecules.. We found that HGF stimulated adhesion of myeloma cells to fibronectin. This event was dependent on the alpha4 and beta1 integrin subunits (VLA-4), but HGF did not increase the expression of integrins on the cell surface. Our findings suggest that HGF promotes myeloma cells to adhere via activation of the phosphatidylinositol 3-kinase (PI3K) pathway independently of AKT, but possibly through the involvement of nuclear factor kappa B (NF-kappaB). INA-6 cells adhered to fibronectin after stimulation by insulin-like growth factor or stromal cell-derived factor 1alpha, but this adhesion was less dependent on PI3K than HGF-mediated adhesion.. his work points to HGF as a pro-adhesive factor in cell adherence to the bone marrow matrix protein fibronectin, an event known to promote cancer cell survival and drug resistance. Inhibiting HGF, its receptor c-Met or the VLA-4 integrin may be beneficial to the myeloma patient.

    Topics: Androstadienes; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Chemokines, CXC; Fibronectins; Hepatocyte Growth Factor; Heterocyclic Compounds, 3-Ring; Humans; Integrin alpha4; Integrin beta1; Multiple Myeloma; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase C; Pyridines; Signal Transduction; Wortmannin

2005
Moving disease biology from the lab to the clinic.
    Cancer, 2003, Feb-01, Volume: 97, Issue:3 Suppl

    Multiple myeloma (MM) cells home to and adhere to extracellular matrix proteins and to bone marrow stromal cells (BMSCs); and in the BM microenvironment, grow, survive, resist drugs, and migrate under the influence of cytokines including interleukin-6, vascular endothelial growth factor, tumor necrosis factor alpha, and insulin-like growth factor (IGF)-1. Proliferation is via the Ras/Raf MAPK cascade, drug resistance via PI3-K/Akt signaling, and migration via PKC dependent pathways. Novel therapies that target not only the MM cell, but also the BM microenvironment, can overcome drug resistance in vitro and in vivo in murine human MM models. For example, immunomodulatory derivatives of thalidomide (IMiDs) and the proteasome inhibitor PS-341 both induce apoptosis of MM cell lines and patient cells refractory to melphalan, doxorubicin, and dexamethasone; abrogate MM cell binding to fibronectin and BMSCs and related protection against immune- and drug-induced apoptosis; block production of cytokines which promote MM cell growth, survival, drug resistance, and migration; inhibit angiogenesis; and stimulate host anti-tumor immunity. In the setting of relapsed refractory MM, a Phase I trial of the IMiD CC5013 shows stable paraprotein or better in 20 of 24 (79%) patients, with a favorable toxicity profile. In this same patient population 85% of 54 patients treated in a Phase II trial of PS-341 achieved either paraprotein response (50%) or stable disease (35%). Cellular and gene microarray studies comparing PS-341 and an IkappaB kinase inhibitor, PS-1145, suggest that selective NF-kappaB blockade cannot account for all the anti-MM activity of PS-341. Finally, cellular and signaling studies provide the preclinical rationale for combining these novel agents with conventional therapies, or with each other, to enhance efficacy. These novel therapeutics therefore represent a new treatment paradigm in MM targeting the tumor cell in its microenvironment to overcome classical drug resistance and improve patient outcome. Future studies should define the utility of these agents as primary therapy, treatment for first relapse, and maintenance therapy.

    Topics: Bone Marrow; Boronic Acids; Bortezomib; Cell Division; Drug Delivery Systems; Heterocyclic Compounds, 3-Ring; Humans; Lenalidomide; Models, Biological; Multiple Myeloma; Protease Inhibitors; Pyrazines; Pyridines; Thalidomide

2003
NF-kappa B as a therapeutic target in multiple myeloma.
    The Journal of biological chemistry, 2002, May-10, Volume: 277, Issue:19

    We have shown that thalidomide (Thal) and its immunomodulatory derivatives (IMiDs), proteasome inhibitor PS-341, and As(2)O(3) act directly on multiple myeloma (MM) cells and in the bone marrow (BM) milieu to overcome drug resistance. Although Thal/IMiDs, PS-341, and As(2)O(3) inhibit nuclear factor (NF)-kappaB activation, they also have multiple and varied other actions. In this study, we therefore specifically address the role of NF-kappaB blockade in mediating anti-MM activity. To characterize the effect of specific NF-kappaB blockade on MM cell growth and survival in vitro, we used an IkappaB kinase (IKK) inhibitor (PS-1145). Our studies demonstrate that PS-1145 and PS-341 block TNFalpha-induced NF-kappaB activation in a dose- and time-dependent fashion in MM cells through inhibition of IkappaBalpha phosphorylation and degradation of IkappaBalpha, respectively. Dexamethasone (Dex), which up-regulates IkappaBalpha protein, enhances blockade of NF-kappaB activation by PS-1145. Moreover, PS-1145 blocks the protective effect of IL-6 against Dex-induced apotosis. TNFalpha-induced intracellular adhesion molecule (ICAM)-1 expression on both RPMI8226 and MM.1S cells is also inhibited by PS-1145. Moreover, PS-1145 inhibits both IL-6 secretion from BMSCs triggered by MM cell adhesion and proliferation of MM cells adherent to BMSCs. However, in contrast to PS-341, PS-1145 only partially (20-50%) inhibits MM cell proliferation, suggesting that NF-kappaB blockade cannot account for all of the anti-MM activity of PS-341. Importantly, however, TNFalpha induces MM cell toxicity in the presence of PS-1145. These studies demonstrate that specific targeting of NF-kappaB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu. Furthermore, they provide the framework for clinical evaluation of novel MM therapies based upon targeting NF-kappaB.

    Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Boronic Acids; Bortezomib; Cell Adhesion; Cell Division; Cell Line; Cells, Cultured; Dexamethasone; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; I-kappa B Kinase; Immunoblotting; Intercellular Adhesion Molecule-1; Models, Chemical; Multiple Myeloma; NF-kappa B; Phosphorylation; Protease Inhibitors; Protein Serine-Threonine Kinases; Pyrazines; Pyridines; Time Factors; Tumor Cells, Cultured; Up-Regulation

2002